These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 11416216

  • 1. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
    Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF.
    Proc Natl Acad Sci U S A; 2001 Jun 19; 98(13):7443-8. PubMed ID: 11416216
    [Abstract] [Full Text] [Related]

  • 2. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.
    Cancer Res; 2006 Feb 01; 66(3):1721-9. PubMed ID: 16452232
    [Abstract] [Full Text] [Related]

  • 3. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
    Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J.
    FASEB J; 2002 Jan 01; 16(1):108-10. PubMed ID: 11729097
    [Abstract] [Full Text] [Related]

  • 4. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.
    Cancer Res; 2005 Oct 15; 65(20):9355-62. PubMed ID: 16230398
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis.
    Zhang YW, Wang LM, Jove R, Vande Woude GF.
    Oncogene; 2002 Jan 10; 21(2):217-26. PubMed ID: 11803465
    [Abstract] [Full Text] [Related]

  • 7. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Met and hepatocyte growth factor/scatter factor expression in human gliomas.
    Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF.
    Cancer Res; 1997 Dec 01; 57(23):5391-8. PubMed ID: 9393765
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
    Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF.
    Oncogene; 2005 Jan 06; 24(1):101-6. PubMed ID: 15531925
    [Abstract] [Full Text] [Related]

  • 12. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
    Jeffers M, Rong S, Anver M, Vande Woude GF.
    Oncogene; 1996 Aug 15; 13(4):853-6. PubMed ID: 8761307
    [Abstract] [Full Text] [Related]

  • 13. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Laterra J.
    Clin Cancer Res; 2006 Feb 15; 12(4):1292-8. PubMed ID: 16489086
    [Abstract] [Full Text] [Related]

  • 14. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.
    Cancer Res; 2000 Jan 15; 60(2):342-9. PubMed ID: 10667586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M.
    Cancer Res; 2000 Nov 01; 60(21):6148-59. PubMed ID: 11085539
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
    Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF.
    Oncogene; 2005 May 26; 24(23):3697-707. PubMed ID: 15782129
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
    Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K.
    Clin Cancer Res; 2003 Oct 01; 9(12):4578-85. PubMed ID: 14555533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.